Understanding the pharmacokinetics and pharmacodynamics of drugs used in psychopharmacology across the paediatric age spectrum from infants to adolescents represents a major challenge for clinicians. In paediatrics, treatment protocols use either standard dose reductions for these drugs for children below a certain age or use less conventional parameters such as weight for allometric dosing. The rationale behind this, however, is often lacking. In this review current available data on the developmental changes in absorption, distribution, metabolism, and elimination of drugs are presented with a specific focus on metabolic pathways, indicating significant differences in the development of enzymes involved in the biotransformation of drugs used in psychopharmacology. Major emphasis will be given to the genetic variation in CYP2D6 activity, the most important enzyme for the metabolism of many psychotropic medications. Lastly, the overview will compile the role of the developmental pharmacologist assuring analytical use of narcotics in offspring as well as youngsters with developmental impairments and in translating pharmacological concepts from the bench to the clinic. To know more Clinical Toxicology and Pharmacology Conference.